Christopher Martin

Christopher Martin is an accomplished pharmaceutical commercial leader with over 25 years of expertise spanning sales, marketing, market access, operations, and business development. Most recently, he served as Chief Commercial Officer at Verona Pharma, a biopharmaceutical company acquired by Merck & Co. in October 2025 that specialized in developing innovative, inhaled therapies for chronic respiratory diseases. Chris previously served as Executive Director of Marketing at SK Life Science, where he was instrumental in developing the commercial and marketing strategy for launching XCOPRI® (cenobamate tablets), a novel CNS therapeutic. Earlier, he was Head of Marketing at Cempra Pharmaceuticals, where he led launch strategy and commercial planning for the company’s first product. Prior to that, he was with Salix Pharmaceuticals in roles of increasing responsibility, including leading the Xifaxan® marketing team. Chris currently serves on the boards of Oruka Therapeutics (Nasdaq: ORKA) and Edgewise Therapeutics (Nasdaq: EWTX). He received a BS in Financial Management from Clemson University.